

**Table 1. Current recommended adjuvant treatment after enucleation for different type of histological risk factors**

Type of histopathological risk factor	Austria and Germany (RB-Registry)	Czech republic	France and Lausanne RB SFCE 09	Israel	The Netherlands	Hospital Vall d'Hebron Spain	United Kingdom
Focal choroidal invasion	none	none	none	none	none	none	none
Massive choroidal invasion	3 VEC (until 2015 6x CyVEC)	6x VEC	2 cycles in total: 2x VCy	6x VEC	6x VEC	6x VEC	4x JOE
Scleral invasion without extraocular disease (S1)	6x VEC (until 2015 6x CyVEC)	6x VEC	4x cycles in total: 2x EC plus 2x VCy	6x VEC	6x VEC	6x VEC	4x JOE
Transscleral extention (S2)	6x VEC plus radiotherapy (until 2015 6x CyVEC + radiotherapy)	6x VEC plus radiotherapy	6 cycles in total: 3x EC plus 3x VCy <sup>HR</sup>  Plus HD chemotherapy and orbital radiotherapy			6x VEC plus radiotherapy	JOE + HD Chemotherapy plus orbital RT 40Gy in 20 fractions - direct anterior field
Prelaminar or intralaminar optic nerve infiltration (N1)	none	none	none	none	none	none	none
Postlaminar optic nerve infiltration (N2)	6x VEC (until 2015 6x CyVEC)	6x VEC	4x cycles in total: 2x EC plus 2x VCy	6x VEC	6x VEC	6x VEC	4x JOE
Infiltration of resection margin of optic nerve (N3)	6x VEC plus radiotherapy (40-50 Gy to the orbit)	6x VEC	6x EC/VCy <sup>HR</sup> High dose Chemotherapy and radiotherapy (45 Gy to the orbit)	6x VEC	6x VEC	6x VEC plus radiotherapy (40 Gy to the orbit)	JOE + HD Chemotherapy plus Radiotherapy (40Gy to the orbit)

definition according to IRSS<sup>13</sup>

JOE/ VEC, vincristine, etoposide and carboplatin

EC, etoposide and carboplatin

VCy, vincristine and cyclophosphamide